Viloxazine hydrochloride for attention deficit disorder with hyperactivity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 5 registered trials.

Why this status

  1. 11 Aug 2017: Trial registered, NCT03247517
  2. 11 Aug 2017: Trial registered, NCT03247530
  3. 11 Aug 2017: Trial registered, NCT03247556
  4. 20 Oct 2017: Trial started, NCT03247530
  5. 2 Nov 2017: Trial started, NCT03247517
  6. 20 Nov 2017: Trial started, NCT03247556
  7. 8 Mar 2021: Trial registered, NCT04786990
  8. 27 Jul 2021: Trial started, NCT04786990

The trials

NCT02633527: Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

State
Completed
Phase
Phase 2
People
222 taking part
Started
1 Feb 2016
Primary completion
25 Jul 2016
Arms
100mg SPN-812, 200mg SPN-812, 300mg SPN-812, 400mg SPN-812
Results
Posted on the registry
  1. 17 Dec 2015: Trial registered
  2. 1 Feb 2016: Trial started
  3. 25 Jul 2016: Trial completed
  4. 27 Oct 2021: Trial results posted

NCT03247517: Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

State
Completed
Phase
Phase 3
People
310 taking part
Started
2 Nov 2017
Primary completion
17 Oct 2018
Arms
200mg SPN-812, 400mg SPN-812
Results
Posted on the registry
  1. 11 Aug 2017: Trial registered
  2. 2 Nov 2017: Trial started
  3. 17 Oct 2018: Trial completed
  4. 18 Jun 2021: Trial results posted

NCT03247530: Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD

State
Completed
Phase
Phase 3
People
477 taking part
Started
20 Oct 2017
Primary completion
12 Sep 2018
Arms
100mg SPN-812, 200mg SPN-812
Results
Posted on the registry
  1. 11 Aug 2017: Trial registered
  2. 20 Oct 2017: Trial started
  3. 12 Sep 2018: Trial completed
  4. 2 Jun 2021: Trial results posted

NCT03247556: Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

State
Completed
Phase
Phase 3
People
297 taking part
Started
20 Nov 2017
Primary completion
14 Feb 2019
Arms
400mg SPN-812, 600mg SPN-812
Results
Posted on the registry
  1. 11 Aug 2017: Trial registered
  2. 20 Nov 2017: Trial started
  3. 14 Feb 2019: Trial completed
  4. 2 Jul 2021: Trial results posted

NCT04786990: Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD

State
Completed
Phase
Phase 4
People
96 taking part
Started
27 Jul 2021
Primary completion
23 May 2023
Arms
Open-Label Treatment
Results
Posted on the registry
  1. 8 Mar 2021: Trial registered
  2. 27 Jul 2021: Trial started
  3. 26 Jul 2023: Trial completed
  4. 1 May 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as 100mg SPN-812, 200mg SPN-812, 300mg SPN-812, 400mg SPN-812, 600mg SPN-812, Qelbree, Vivalan.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.